MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 滬
等待開盤 10-10 09:30:00 美东时间
10.90
+3.190
+41.37%
華盛通- 最 高11.88
- 今 開9.41
- 成交量 624.76万股
- 最 低 9.00
- 昨 收 7.71
- 總市值 675.26万
- 52周最高 92.00
- 市盈率 靜 --
- 換手率 1008.49%
- 52周最低 5.0001
- 委 比 67.70%
- 總股本 61.95万
- 歷史最高 159417654.2112
- 量 比 120.15
- 振 幅 37.35%
- 歷史最低 7.846
- 每 手 1
- 風險率 19.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
10-09 20:07
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Biodexa Pharmaceuticals PLC will host a breakfast symposium on FAP mechanisms and chemoprevention trial issues at the CGA-IGC conference on October 11, 2025, in St. Louis, MO. Featuring guest speaker Dr. Patrick Lynch and a panel discussion with Drs. Sonia Kupfer and Paul Wise, the event aims to advance FAP treatment options and support Biodexa's Phase 3 Serenta trial for eRapa. Biodexa is focused on developing innovative therapies for unmet medi...
10-06 12:30
Biodexa Pharmaceuticals Files For Mixed Shelf Of Up To $100M
https://www.sec.gov/Archives/edgar/data/1643918/000121465925014255/b923250f3.htm
09-27 05:04
Biodexa Pharmaceuticals Advances Serenta Trial and Secures Financial Backing
An announcement from Biodexa Pharmaceuticals ( ($BDRX) ) is now available. Biod...
09-12 21:33
Biodexa Pharmaceuticals GAAP EPS of -£0.0002
Biodexa Pharmaceuticals press release (NASDAQ:BDRX): 1H GAAP EPS of -£0.0002. Net cash used in operating activities (after changes in working capital) in 1H25 was £3.30 million (1H24: £4.81 million). ...
09-12 20:43
Biodexa Pharmaceuticals Begins Phase 3 Trial for FAP Treatment
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On August 18...
08-18 20:57
Biodexa Pharmaceuticals Implements ADR Ratio Change
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an update. On July 31, 2025, ...
07-31 21:59
Biodexa Pharma Advances Development eRapa, Oral Tablet Formulation Of Rapamycin, To Treat FAP Non-Surgically
Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in developing eRapa, an oral tablet formulation of rapamycin, to treat FAP non-surgically. eRapa
07-28 19:10
ADR Ratio Change
On July 15, 2025, Biodexa Pharmaceuticals PLC announced a ratio change for its American Depositary Receipts (ADR), adjusting from 1 ADR representing 10,000 ordinary shares to 1 ADR representing 100,000 ordinary shares, effective July 31, 2025. ADR holders must exchange 10 old ADRs for 1 new ADR. This change aims to align the ADR price with Nasdaq's $1.00 minimum bid price requirement, though success is not guaranteed. Forward-looking statements a...
07-15 20:30
Biodexa Pharma Files CTA With EMA For Serenta Trial In Patients With Familial Adenomatous Polyposis
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial inFamilial Adenomatous Polyposis (FAP)Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical
07-14 20:35
